Subscription Center
Jul 30, 2008
A drug called PBT2, developed by Australian company Prana Biotechnology, appears to improve cognitive abilities in patients with early-stage Alzheimer's disease. Researchers report in Lancet Neurology, that it was also successful in reducing protein buildup associated with the debilitating neurodegenerative illness, which plagues up to 4.5 million Americans.
Craig Ritchie, a neuroscientist at Imperial College London and Prana consultant, says that the success of the recent 12-week trial (which had 78 participants) -- must be replicated in a larger longer-term trial before the company would consider seeking approval to sell it as an Alzheimer's therapy. "Our hope is that we might be able to see treatments that can substantially improve the lives of people with Alzheimer's disease within the next five or so years," he said in a statement.
See what we're tweeting about
BoraZ RT @Protohedgehog: An interesting look at the evolution of science authorship through time, by @RobAboukhalil http://t.co/yol4Ko3ssY BoraZ RT @mistersugar: ICYMI: Please help us understand the impact of @ScienceOnline. #sciox. http://t.co/A4T1wYtKCi BoraZ China's One-Child Policy Affects Personality: http://t.co/Hu9pfKjMce
Deadline: Jun 30 2013
Reward: $1,000,000 USD
This is a Reduction-to-Practice Challenge that requires written documentation and&
Deadline: Jul 25 2013
Reward: Varies
This challenge provides an opportunity for Solvers to build a web-based or mobile “app” to explore data relationships in scholarly conte
Powered By: 
YES! Send me a free issue of Scientific American with no obligation to continue the subscription. If I like it, I will be billed for the one-year subscription.
